Figure 1.
Mean (± SD) plasma concentrations of flubendazole (FLBZ) and its reduced (R-FLBZ) and hydrolyzed (H-FLBZ) metabolites following subcutaneous (sc) administration of FLBZ-CD solution (5 mg/kg) to uninfected rats (n = 4 per time point).
Figure 2.
Mean (± SD) plasma concentrations of flubendazole (FLBZ) and its reduced (R-FLBZ) and hydrolyzed (H-FLBZ) metabolites following subcutaneous (sc) administration of FLBZ-CD solution (5 mg/kg) to uninfected jirds (n = 4 per time point).
Figure 3.
Comparative flubendazole (FLBZ) mean (± SD) plasma concentration profiles obtained after administration of different formulations to uninfected rats (n = 4 per time point). Insert shows the pharmacokinetic parameters AUC 0-t and Cmax (µg/mL) estimated for FLBZ. Different letters indicate statistically significant differences (P<0.05) between experimental groups.
Table 1.
Pharmacokinetic parameters (mean ± SD) obtained for flubendazole (FLBZ) and its hydrolyzed metabolite (H-FLBZ) after treatment (5 mg/kg) with different FLBZ formulations to uninfected rats: Cyclodextrin-based (FLBZ-CDoral or FLBZ-CDsc), Tween-based (FLBZ-TWEEN) and carboxy methylcellulose-based (FLBZ-CMC).
Figure 4.
Comparative flubendazole (FLBZ) mean (± SD) plasma concentration profiles obtained after administration of different formulations to uninfected jirds (n = 4 per time point). Insert shows the pharmacokinetic parameters AUC 0-t and Cmax (µg/mL) estimated for FLBZ parent drug. Different letters indicate statistically significant differences (P<0.05) between experimental groups.
Figure 5.
Relative systemic exposure (area under concentration vs. time curve, AUC 0-t) of flubendazole (FLBZ) and its reduced (R-FLBZ) and hydrolyzed (H-FLBZ) metabolites in different animal species treated orally with a FLBZ-CD solution.
Data taken from Ceballos et al, 2009 (1), 2012 (a) (2), 2012 (b) (3).
Table 2.
Pharmacokinetic parameters (mean ± SD) obtained for flubendazole (FLBZ) after its administration (5 mg/kg) as different formulations to uninfected jirds: Cyclodextrin-based (FLBZ-CDoral or FLBZ-CDsc) and Tween-based (FLBZ-TWEEN) formulations.